Thomson Reuters Launches New Predictive Pharmacology Module As Part Of Its Prous Science Integrity Platform
London, UK - August 28, 2008 — The Scientific business of Thomson Reuters today announced the launch of the Prous Science Integrity® Predictive Pharmacology Module. This new tool, available through the Prous Science Integrity platform,provides expert scientific insight into the probable mechanisms of action of thousands of bioactive compounds.
The Predictive Pharmacology Module is based on robust technology developed at the Prous Institute for Biomedical Research, a state-of-the-art research organization focused on experimental and data-mining methods. The module details up to three potential mechanisms of action for nearly 100,000 lead compounds with chemical structures in and includes unique visualization tools. The module will help to accelerate experimental research and identify new indications for existing drugs before they reach trial stage by allowing scientists to validate new drug discovery hypotheses and become aware of mechanisms of action that may cause adverse effects. In addition, it can be used by business development analysts for pharmaceutical companies to develop drug repurposing strategies.
“Accelerating drug discovery and increasing the potential uses and reach of existing molecules are key challenges for the Pharmaceutical and Biotechnology industries,” said Dr. Josep Prous, Jr., Vice President and Chief Scientific Officer of the Scientific Business of Thomson Reuters. Prous Science Integrity’s Predictive Pharmacology Module was designed with the needs of medicinal chemists and experimental pharmacologists in mind, helping them to discover at a very early stage the full range of possible uses for the compounds they’re researching. This will greatly benefit innovators by providing potential new indications for existing compounds, which could cut years of research and testing.”
The Predictive Pharmacology Module highlights new discovery opportunities through three innovative components:
The Predictive Pharmacology component assists in the discovery of unknown mechanisms of action for compounds with a demonstrated therapeutic effect. It allows end-users to discriminate between active and inactive compounds for specific pharmacological activities and also to determine areas in which recently patented or established compounds can be repurposed.
The Discovery Maps component enables end-users to visually analyze data and discover wider relationships.
The Molecular Datacenter component enables end-users to search for and display constitutional, topological, and physicochemical property descriptors.
For further information about this new module, please go to: thomsonreuters.com/products_services/scientific/Prous_Science_Integrity_Predict
The Scientific business of Thomson Reuters will be organizing demonstrations of the Predictive Pharmacology Module at EFMC-ISMC 2008 – the 20th International Symposium on Medicinal Chemistry, Vienna, Austria, 31st August – 4th September 2008 (stand number 51-52). >
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com